NCT02612220 (BioFoam) is a NA clinical trial of BioFoam® Surgical Matrix in Hemorrhage, sponsored by Technische Universität Dresden.

Who is sponsoring NCT02612220?

NCT02612220 is sponsored by Technische Universität Dresden.

What drugs are being tested in NCT02612220?

Interventions in NCT02612220: BioFoam® Surgical Matrix, Conservative hemostasis.

What condition does NCT02612220 study?

NCT02612220 studies Hemorrhage.

Is NCT02612220 still recruiting?

NCT02612220 is currently completed. Last updated 20 October 2017.

Last reviewed 2017-10-20 · How we verify

NCT02612220: BioFoam

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effectiveness of BioFoam® Surgical Matrix to Improve Hemostasis During Liver Resection

Completed NA Last updated 20 October 2017

What this trial tests

NA trial testing BioFoam® Surgical Matrix in Hemorrhage in 101 participants. Completed in 6 September 2017.

Timeline

3 December 2015

Primary endpoint
6 September 2017

6 September 2017

Quick facts

Lead sponsor	Technische Universität Dresden
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	101
Start date	3 December 2015
Primary completion	6 September 2017
Estimated completion	6 September 2017
Sites	1 location across Germany

Drugs / interventions tested

BioFoam® Surgical Matrix
Conservative hemostasis

Conditions studied

Hemorrhage — all drugs for Hemorrhage →

Sponsor

Technische Universität Dresden — full company profile →

Who can join

18 and older, any sex, with Hemorrhage. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present randomized controlled trial evaluates the efficacy and safety of BioFoam® Surgical Matrix in patients undergoing elective liver resection. In contrast to other topical agents, the surgical adhesive BioFoam® Surgical Matrix may not only accelerate hemostasis but also facilitate sealing of bile ducts and thus has the potential to reduce the incidence of postoperative complications. The primary objective of this trial is to show that time-to-complete hemostasis can be reduced using BioFoam® Surgical Matrix as compared to the conventional approach.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Randomized clinical trial of BioFoam® Surgical Matrix to achieve hemostasis after liver resection.
Rahbari NN, Birgin E, Sturm D, Schwanebeck U, et al · · 2020 · cited 10× · PMID 31680010 · DOI 10.1016/j.hpb.2019.10.1529
Infrahepatic Inferior Vena Cava Clamping does not Increase the Risk of Pulmonary Embolism Following Hepatic Resection.
Birgin E, Mehrabi A, Sturm D, Reißfelder C, et al · · 2021 · cited 7× · PMID 34047820 · DOI 10.1007/s00268-021-06159-4

Verify or expand the search:

Other recruiting trials for Hemorrhage

Currently open trials in the same condition.

NCT07311343 — Oral Hygiene and Prophylactic Antibiotics to Prevent Intracerebral Hemorrhage Associated Pneumonia · Phase 4 · recruiting
NCT07105904 — Biological and Clinical Relevance of Quantra Viscoelastic Hemostatic Assay in Hemorrhagic Cardiac Surgery · active not recruiting
NCT06979466 — Q Therapeutic System for Chronic Stroke Recovery · NA · recruiting
NCT06664775 — A Study to Compare the Efficacy and Safety of TachoSil and Surgicel Original as an Adjunct to Control Mild to Moderate S · Phase 3 · recruiting
NCT06304714 — Effects of Bothrops Spp. Snake Envenomation on Willebrand Factor Activity in Martinique and French Guiana · recruiting

Other Technische Universität Dresden trials

Trials by the same sponsor.

NCT07150598 — Immune-Marker Platform for Patients With Advanced Lung Cancer · not yet recruiting
NCT06717958 — Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute M · Phase 2 · recruiting
NCT06701487 — Role of Pavlovian Mechanisms for Control Over Substance Use · recruiting
NCT03865277 — Individualized Radiation Dose Prescription in HNSCC Based on F-MISO-PET Hypoxia-Imaging · Phase 2 · not yet recruiting
NCT06293170 — Automated Screening for Clinically Ascertained Loss of Cerebral Functions · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02612220 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Technische Universität Dresden
Last refreshed: 20 October 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02612220.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing